Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer

Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer

Abstract CDK4/6i, the first-line drug for treating ERα-positive breast cancer, significantly improves clinical outcomes. However, CDK4/6i resistance often develops and remains a major hurdle, and the underlying mechanisms remain challenging to fully investigate. Here, we used Genome-wide CRISPR/Cas9...

Full description

Saved in:
Bibliographic Details
Main Authors: Chenlin Liu, Dong Fan, Jiahui Sun, Guodong Li, Ruoxin Du, Xiaoshuang Zuo, Kuo Zhang, Wangqian Zhang, Shuning Wang, Xiaojv Li, Mingrui Du, Donghui Wang, Qiang Hao, Yingqi Zhang, Meng Li, Cun Zhang, Yuan Gao
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Nanobiotechnology
Subjects:
RNA modification
m6A
METTL14
Breast cancer
Online Access:https://doi.org/10.1186/s12951-024-03021-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12951-024-03021-2

Similar Items